Friday, July 10, 2026

Drug profile · INN

quinupristin

quinupristin (SYNERCID) is a bacterial 70s ribosome inhibitor. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — quinupristin
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

quinupristin (SYNERCID) is a bacterial 70s ribosome inhibitor. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN quinupristin
Brand SYNERCID
Mechanism Bacterial 70S ribosome inhibitor
Target Bacterial 70S ribosome
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Bacterial 70S ribosome inhibitor

Primary target: Bacterial 70S ribosome

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. azithromycin Bacterial 70S ribosome inhibitor
  2. chloramphenicol Bacterial 70S ribosome inhibitor
  3. clarithromycin Bacterial 70S ribosome inhibitor
  4. clindamycin hydrochloride Bacterial 70S ribosome inhibitor
  5. clindamycin palmitate hydrochloride Bacterial 70S ribosome inhibitor
  6. clindamycin phosphate Bacterial 70S ribosome inhibitor

Frequently asked questions

What is quinupristin?

quinupristin (SYNERCID) is a bacterial 70s ribosome inhibitor. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for quinupristin?

SYNERCID is a marketed brand name for quinupristin. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of quinupristin?

quinupristin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.